Botulinum type A2 toxin - Shionogi

Drug Profile

Botulinum type A2 toxin - Shionogi

Alternative Names: 150kDa botulinum type A toxin - Kaketsuken; A2NTX; Botulinum type A toxin (150kDa) - Kaketsuken; LMW botulinum type A toxin; Low molecular weight botulinum type A toxin; NTX

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kaketsuken; University of Tokushima
  • Developer Kaketsuken; Shionogi; University of Tokushima
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Muscle spasticity
  • Discontinued Dystonia

Most Recent Events

  • 11 Dec 2017 Discontinued - Clinical-Phase-Unknown for Dystonia in Japan (Intradermal) (Kaketsuken pipeline, December 2017)
  • 15 Mar 2016 Biomarkers information updated
  • 17 Dec 2007 No development reported - Clinical-Phase-Unknown for Dystonia in Japan (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top